Literature DB >> 12742303

Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome.

Inas Al-Attar1, E John Orav, Vernat Exil, Sarah A Vlach, Steven E Lipshultz.   

Abstract

OBJECTIVES: The aim of this study was to determine the prevalence of cardiovascular dysfunction and its predictors in children with acquired immunodeficiency syndrome (AIDS).
BACKGROUND: Cardiovascular manifestations are common among children with AIDS but may be clinically occult.
METHODS: We reviewed the medical records, echocardiograms, electrocardiograms, and Holter monitor studies of 68 children with AIDS. We tested clinical and demographic characteristics at the time of AIDS diagnosis for their ability to predict serious cardiac events, death, and cardiac death.
RESULTS: The median time from AIDS diagnosis to death or end of follow-up was 1.0 year (range, 1 week to 7.9 years). Nineteen patients (28%) experienced serious cardiac events after AIDS diagnosis. Of 43 patients who died, 15 (35%) had cardiac dysfunction. Multivariable analyses revealed that recurrent bacterial infections, wasting, encephalopathy, male gender, and an earlier year of AIDS diagnosis were predictors of serious cardiac events (relative risk [RR] = 9.3, 6.9, 4.7, 4.1, and 0.76, respectively, p < 0.05). Wasting, encephalopathy, a low age-adjusted CD4 count, a low age-adjusted immunoglobulin G (IgG) level, and an earlier year of AIDS diagnosis increased the risk of all-cause mortality (RR = 8.9, 5.1, 2.7, 0.82, and 0.8, respectively, p <or= 0.02). Male gender, a low age-adjusted CD4 count, and a low age-adjusted IgG level increased the risk for cardiac death (RR = 16.9, 4.2, and 0.68, respectively, p <or= 0.05).
CONCLUSIONS: Serious cardiac events and cardiac death are common among children with AIDS. Factors such as recurrent bacterial infections, wasting, encephalopathy, male gender, low CD4 and IgG levels, and an earlier year at AIDS diagnosis may identify high-risk patients.

Entities:  

Mesh:

Year:  2003        PMID: 12742303     DOI: 10.1016/s0735-1097(03)00256-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

1.  Resolution of dilated cardiomyopathy in an adolescent with change of a failing highly active antiretroviral drug therapy.

Authors:  Twalib Olega Aliku; Sulaiman Lubega; Peter Lwabi
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

2.  Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study).

Authors:  Steven E Lipshultz; William T Shearer; Bruce Thompson; Kenneth C Rich; Irene Cheng; E John Orav; Sulekha Kumar; Ricardo H Pignatelli; Louis I Bezold; Philip LaRussa; Thomas J Starc; Julie S Glickstein; Sharon O'Brien; Ellen R Cooper; James D Wilkinson; Tracie L Miller; Steven D Colan
Journal:  J Am Coll Cardiol       Date:  2011-01-04       Impact factor: 24.094

3.  State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary.

Authors:  Steven K Grinspoon; Carl Grunfeld; Donald P Kotler; Judith S Currier; Jens D Lundgren; Michael P Dubé; Steven E Lipshultz; Priscilla Y Hsue; Kathleen Squires; Morris Schambelan; Peter W F Wilson; Kevin E Yarasheski; Colleen M Hadigan; James H Stein; Robert H Eckel
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

4.  Cardiac and inflammatory biomarkers in perinatally HIV-infected and HIV-exposed uninfected children.

Authors:  James D Wilkinson; Paige L Williams; Wendy Yu; Steven D Colan; Armando Mendez; Justin P V Zachariah; Russell B Van Dyke; William T Shearer; Renee E Margossian; Steven E Lipshultz
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

5.  Reduced diastolic function and left ventricular mass in HIV-negative preadolescent children exposed to antiretroviral therapy in utero.

Authors:  W Todd Cade; Alan D Waggoner; Sara Hubert; Melissa J Krauss; Gautam K Singh; E Turner Overton
Journal:  AIDS       Date:  2012-10-23       Impact factor: 4.177

6.  Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P2C2 HIV Multicenter Study.

Authors:  Stacy D Fisher; Kirk A Easley; E John Orav; Steven D Colan; Samuel Kaplan; Thomas J Starc; J Timothy Bricker; Wyman W Lai; Douglas S Moodie; George Sopko; Steven E Lipshultz
Journal:  Am Heart J       Date:  2005-09       Impact factor: 4.749

7.  Nutrition in Pediatric Cardiomyopathy.

Authors:  Tracie L Miller; Daniela Neri; Jason Extein; Gabriel Somarriba; Nancy Strickman-Stein
Journal:  Prog Pediatr Cardiol       Date:  2007-11

8.  Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study.

Authors:  Steven E Lipshultz; Paige L Williams; James D Wilkinson; Erin C Leister; Russell B Van Dyke; William T Shearer; Kenneth C Rich; Rohan Hazra; Jonathan R Kaltman; Denise L Jacobson; Laurie B Dooley; Gwendolyn B Scott; Nicole Rabideau; Steven D Colan
Journal:  JAMA Pediatr       Date:  2013-06       Impact factor: 16.193

9.  Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption of antiretroviral therapy.

Authors:  Emmanouil Papasavvas; Livio Azzoni; Maxwell Pistilli; Aidan Hancock; Griffin Reynolds; Cecile Gallo; Joe Ondercin; Jay R Kostman; Karam Mounzer; Jane Shull; Luis J Montaner
Journal:  AIDS       Date:  2008-06-19       Impact factor: 4.177

10.  Cardiac Effects of Highly Active Antiretroviral Therapy in Perinatally HIV-Infected Children: The CHAART-2 Study.

Authors:  Steven E Lipshultz; James D Wilkinson; Bruce Thompson; Irene Cheng; David A Briston; William T Shearer; E John Orav; Joslyn A Westphal; Tracie L Miller; Steven D Colan
Journal:  J Am Coll Cardiol       Date:  2017-10-31       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.